Home > Insider Trading > Filing (0000899243-20-024407)

Filing Details

Accession Number:: 0000899243-20-024407
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-09-04 21:01:36
Reporting Period:: 2020-09-02

Accepted Time:: 2020-09-04 21:01:36
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
896262	Amedisys Inc	AMED	Services-Home Health Care Services (8082)	113131700

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1743787	Sharon Brunecz	3854 American Way, Suite A Baton Rouge LA 70816	Chief Human Resources Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-09-02	4,367	$93.76	22,100	No	4	M	Direct
Common Stock	Disposition	2020-09-02	635	$242.01	21,465	No	4	S	Direct
Common Stock	Disposition	2020-09-02	1,282	$243.53	20,183	No	4	S	Direct
Common Stock	Disposition	2020-09-02	103	$244.88	20,080	No	4	S	Direct
Common Stock	Disposition	2020-09-02	724	$246.17	19,356	No	4	S	Direct
Common Stock	Disposition	2020-09-02	1,538	$247.78	17,818	No	4	S	Direct
Common Stock	Disposition	2020-09-02	85	$248.37	17,733	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-09-02	4,367	$0.00	4,367	$93.76

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
8,734		2028-07-27	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	117	Indirect	Through 401(k) Plan

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $241.65 to $242.45, inclusive. The reporting person undertakes to provide toAmedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate pricewithin the ranges set forth in footnote (2) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.04 to $244.01, inclusive. The reporting person undertakes to provide tothe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges setforth in footnote (3) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.88 to $245.03, inclusive. The reporting person undertakes to provide tothe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges setforth in footnote (4) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.05 to $246.58, inclusive. The reporting person undertakes to provide tothe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges setforth in footnote (5) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.34 to $248.24, inclusive. The reporting person undertakes to provide tothe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges setforth in footnote (6) to this Form 4.
The information in this report is based on a plan statement dated as of June 30, 2020.
On July 27, 2018, the reporting person was granted an option to purchase 17,468 shares of common stock, subject to time-based vesting. 4,367 of the options vested on each of July 27, 2019 and July 27, 2020,and the remaining 8,734 options vest ratably on each of July 27, 2021 and July 27, 2022, provided that the reporting person remains continuously employed by the Issuer on each such date, subject to pro-ratedvesting provisions as provided in the award agreement for the stock options.